

You may be eligible to participate in the AVT001 trial if you:

- Were diagnosed with Type 1 Diabetes within the last 12 months
- Are age 18 or older
- Are not pregnant, breastfeeding, or planning to become pregnant during the duration of the trial



Study sponsor: Avotres, Inc.

Approved by
JDC/ CHS

This trial is available at:



For more information or to schedule an appointment, please call:

(888) 813-8669

Or email us at:

T1DTrials@joslin.harvard.edu



**Joslin Diabetes Center
One Joslin Place
Boston, MA
02215**

Were you recently diagnosed with Type 1 Diabetes?



AVT001 Cell-Based Therapy in Type 1 Diabetes

Why are we doing this trial?

Most people with Type 1 Diabetes have a measurable problem with a group of immune regulatory cells.

Our goal is to determine if we can safely correct this immune regulatory problem and reduce the immune system's attack on the insulin-producing beta cells.



Approved by
JDC/ CHS


The Approach

Your own blood cells will be used to develop a treatment specific to you.

The AVT001 trial is randomized. Two thirds of participants will be assigned to receive the active treatment, and one third will receive an inactive placebo. You will not know which group you are in.

Procedures include examinations, cell collection, treatment infusions, mixed meal tolerance tests to monitor beta cell function, and other blood tests.

Follow up assessments will evaluate if treatment corrects the immune defect and preserves beta cell function.



Approximate 2 Year Commitment